SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Shin Nippon Biomedical Laboratories, Ltd.

2395

JP3379950003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 11/07/2024 BST			5-day change	1st Jan Change
1,324 ^JPY	+0.76%		-5.50%	-22.03%

07-05	Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit	MT
07-05	Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 1,500 Yen From 2,800 Yen	MT

Biomy, Inc, announced that it has received funding from Shin Nippon Biomedical Laboratories, Ltd.

August 22, 2022

biomy, Inc, announced that it has raised a round of funding from Shin Nippon Biomedical Laboratories, Ltd. on August 23, 2022.

Latest news about Shin Nippon Biomedical Laboratories, Ltd.

Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit	07-05	MT
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 1,500 Yen From 2,800 Yen	07-05	MT
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02-02	CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	01-18	MT
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02/08/23	CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15/06/23	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	07/06/23	CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen	29/05/23	MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08/05/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08/05/23	CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen	18/04/23	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23	MT
Sector Update: Health Care Stocks Higher Premarket Monday	17/04/23	MT
Bank Earnings in Focus as US Equity Futures Tread Water	17/04/23	MT
Top Premarket Gainers	17/04/23	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17/04/23	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	16/04/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	31/01/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	31/10/22	CI
Biomy, Inc, announced that it has received funding from Shin Nippon Biomedical Laboratories, Ltd.	22/08/22	CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022	29/07/22	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022	29/07/22	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of Ina Research Inc. from its shareholders.	12/07/22	CI
Shin Nippon Biomedical Laboratories, Ltd. made a tender offer to acquire Ina Research Inc. from its shareholder for ¥2.7 billion.	31/05/22	CI

Chart Shin Nippon Biomedical Laboratories, Ltd.

Duration

Period

Chart Shin Nippon Biomedical Laboratories, Ltd.

More charts

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,324 JPY

Average target price

1,500 JPY

Spread / Average Target

+13.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	-22.03%	338M
MODERNA, INC.	+23.50%	45.01B
LONZA GROUP AG	+47.19%	40.96B
IQVIA HOLDINGS INC.	-5.16%	38.62B
ALNYLAM PHARMACEUTICALS, INC.	+36.37%	32.6B
CELLTRION, INC.	-7.79%	27.49B
ICON PUBLIC LIMITED COMPANY	+18.06%	27.17B
UNITED THERAPEUTICS CORPORATION	+47.29%	14.61B
MEDPACE HOLDINGS, INC.	+41.91%	12.95B
BIO-TECHNE CORPORATION	-1.02%	11.36B

Other Biotechnology & Medical Research

Shin Nippon Biomedical Laboratories, Ltd.

Equities

2395

JP3379950003

Biotechnology & Medical Research

Biomy, Inc, announced that it has received funding from Shin Nippon Biomedical Laboratories, Ltd.

Latest news about Shin Nippon Biomedical Laboratories, Ltd.

Chart Shin Nippon Biomedical Laboratories, Ltd.

Company Profile

Income Statement Evolution

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research